- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04648046
CAR-T Cells for HIV Infection
Safety and Anti-HIV Activity of Autologous CD4+ and CD8+ T Cells Transduced With a Lentiviral Vector Encoding Bi-specific Anti-gp120 CAR Molecules (LVgp120duoCAR-T) in Anti-retroviral Drug-treated HIV-1 Infection
Study Overview
Status
Conditions
Detailed Description
A limited-center, open-label dose escalating phase I/IIa study of autologous T cells expressing LVgp120duoCAR molecules will be performed. Participants will be enrolled sequentially in up to three cohorts following a 3+3 design. Dose escalation decisions will be made when a minimum of three participants have completed the safety-evaluation period (45 days) at a given dose level. No dose escalation will be allowed in an individual participant, and participants who have dose limiting adverse events will reinstate ART therapy at first available opportunity.
Following a 3+3 design, each cohort will enroll at least 3 participants. If there are no safety issues with dosing in a cohort, the investigators will proceed to the following cohort. If one participant in a cohort experiences a safety issue, an additional 3 individuals will be enrolled in that cohort to assess safety prior to proceeding to the next cohort. See below for Dose Escalation Procedures.
The first 3 participants start at Cohort 1. Data from Cohort 1 will be submitted for FDA review prior to dosing Cohorts 2 and 3 to determine if cyclophosphamide conditioning is needed.
Cohort 1: Participants will NOT undergo non-ablative conditioning with cyclophosphamide. A single dose of 3 x 105 cells/kg LVgp120duoCAR-T cells will be infused. ART will be interrupted immediately after infusion.
Cohort 2: Participants will undergo non-ablative conditioning with cyclophosphamide. A single dose of 3 x 105 cells/kg LVgp120duoCAR-T cells will be infused. ART will be interrupted immediately after infusion.
Cohort 3: Participants will undergo non-ablative conditioning with cyclophosphamide. A single dose of 1 x 106 cells/kg LVgp120duoCAR-T cells will be infused into the participant. ART will be interrupted immediately after infusion.
Dose Escalation Procedures:
- If, after 45 days of study treatment, no participant out of the initial 3 in a cohort exhibits a study treatment-related DLT, then the next cohort of participants will be treated at the subsequent cohort.
- If, after 45 days of study treatment, 1 participant out of the initial 3 in a cohort exhibits a study treatment-related DLT, then up to 3 additional participants will be added at that dose level.
- If no additional participant develops a study treatment-related DLT (i.e., 1/6 participants with DLT at that dose level), then the next cohort of participants will be treated at the next higher dose level.
- However, if a second participant develops a study treatment-related DLT, even if it is before there are 6 total participants on that level, then the maximum tolerated dose (MTD) has been exceeded and no additional participants should be added to this or any higher doses. A total of 6 participants should then be treated on the next lowest dose level to ensure its tolerability and to better define the MTD. Thus, the MTD is defined as the highest assigned dose level at which < 2/6 participants have a DLT.
- If 2 participants in Cohort 1 experience a related DLT, the MTD will have been exceeded and no additional participants will be added at any higher level.
- If the investigators experience DLTs in Cohort 1, the investigators will de-escalate the dose to 1 x 10^5 cells per kg. If the investigators experience DLTs at the de-escalated dose of 1 x 10^5 cells per kg, the study will stop.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Rebecca Hoh
- Phone Number: 139 415-476-4082
- Email: rebecca.hoh@ucsf.edu
Study Locations
-
-
California
-
Sacramento, California, United States, 95817
- Recruiting
- University of California, Davis
-
Contact:
- Christina Dyner, RN
- Email: cjdyer@ucdavis.edu
-
Principal Investigator:
- Mehrdad Abedi
-
San Francisco, California, United States, 94110
- Recruiting
- Zuckerberg San Francisco General
-
Contact:
- Rebecca Hoh, MS
- Phone Number: 139 415-476-4082
- Email: rebecca.hoh@ucsf.edu
-
Principal Investigator:
- Steven Deeks, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female, age ≥ 18 and ≤ 65 years
- HIV-1 infection
- On continuous antiretroviral therapy for at least 12 months without any interruptions of greater than 14 consecutive days, and on a stable regimen that does not include a non-nucleoside reverse transcriptase inhibitor (NNRTI) for at least 4 weeks or any long-acting ART drug that may be active in the participant after ART interruption for up to one year, without plans to modify ART during the study period
- Screening plasma HIV RNA levels below the limit of quantification on all available determinations in past 12 months (isolated single values ≥ 40 but < 200 copies/mL will be allowed if they were preceded and followed by undetectable viral load determinations)
- CD4+ T cell count nadir > 300 cells/mm3
- Screening CD4+ T-cell count ≥ 500 cells/mm3
- Available ART treatment history and the capacity to construct an effective antiretroviral treatment regimen
- Willing to pause ART as part of the study
Exclusion Criteria:
- Pregnant, breastfeeding, or unwilling to practice birth control during participation in the study
- ART regimen that includes a long-acting anti-HIV drug and/or NNRTI that may be active in the participant for up to one year after ART interruption
- ART regimen that includes protease inhibitor(s) and/or AZT. These drugs may increase the toxicity of cyclophosphamide.
- Any history of an HIV-associated malignancy, including Kaposi's sarcoma and any type of lymphoma, or virus-associated cancers
- History of or current active hepatitis B (HBV) infection defined as positive HBV surface antigen test. A positive anti-HBc regardless of HBsAg status.
- Active hepatitis C (HCV) infection
- Active or latent tuberculosis infection
- Chronic liver disease
- Active and poorly controlled atherosclerotic cardiovascular disease
- Unwillingness to abstain from sex or use barrier protection for any sexual activity during the treatment interruption.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Low Dose CAR-T Cells Only
Participants will NOT undergo non-ablative conditioning with cyclophosphamide.
A single dose of 3 x 10^5 cells/kg LVgp120duoCAR-T cells will be infused.
ART will be interrupted immediately after infusion.
|
A single dose of 3 x 10^5 cells/kg LVgp120duoCAR-T cells will be infused.
HIV antiretroviral therapy medications will be paused.
|
Experimental: Conditioning + Low Dose CAR-T Cells
Participants will undergo non-ablative conditioning with cyclophosphamide.
A single dose of 3 x 10^5 cells/kg LVgp120duoCAR-T cells will be infused.
ART will be interrupted immediately after infusion.
|
A single dose of 3 x 10^5 cells/kg LVgp120duoCAR-T cells will be infused.
HIV antiretroviral therapy medications will be paused.
Non-ablative conditioning with cyclophosphamide.
|
Experimental: Conditioning + High Dose CAR-T Cells
Participants will undergo non-ablative conditioning with cyclophosphamide.
A single dose of 1 x 10^6 cells/kg LVgp120duoCAR-T cells will be infused into the participant.
ART will be interrupted immediately after infusion.
|
HIV antiretroviral therapy medications will be paused.
Non-ablative conditioning with cyclophosphamide.
A single dose of 1 x 10^6 cells/kg LVgp120duoCAR-T cells will be infused.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants reporting a new Grade 3 or greater adverse event that is definitely, probably, or possibly related to study treatment within 1 year of product administration.
Time Frame: Within 1 year of product administration
|
The primary safety outcome will be the number of participants reporting a new Grade 3 or greater adverse events assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 3.0, including signs/symptoms, lab toxicity or clinical event, that is definitely, probably, or possibly related to study treatment within 1 year of product administration.
|
Within 1 year of product administration
|
Number of participants achieving post-treatment control within 36 weeks of product administration.
Time Frame: Week 36
|
The primary efficacy outcome will be the proportion of individuals who achieve study-defined post-treatment control.
The investigators will define post-treatment control in two ways.
First, participants who fail to show any consistent rebound above 400 copies RNA/mL between Weeks 12 and Week 36 will be considered as having achieved post-treatment control.
Second, participants who exhibit a rebound and eventually achieve 24 weeks of virus control will be considered as having achieved post-treatment control.
|
Week 36
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Persistence of LVgp120duoCAR-T cells in blood during therapy
Time Frame: Week 12 through Week 36
|
Real-time quantitative polymerase chain reaction (qPCR) will be used to monitor the frequency of circulating CD4+ and CD8+ T cells harboring the integrated LVgp120duoCAR-T gene longitudinally to determine product persistence.
This measure will be performed on blood samples.
|
Week 12 through Week 36
|
Persistence of LVgp120duoCAR-T cells in tissues during therapy
Time Frame: Week 12 through Week 36
|
Real-time quantitative polymerase chain reaction (qPCR) will be used to monitor the frequency of circulating CD4+ and CD8+ T cells harboring the integrated LVgp120duoCAR-T gene longitudinally to determine product persistence.
This measure will be performed on tissue samples collected from volunteers agreeing to lymph node sampling.
|
Week 12 through Week 36
|
Change in quantitative virologic measures of the HIV reservoir pre- and post-therapy
Time Frame: Baseline and 36 weeks
|
The HIV reservoir will be measured using methods such as quantitative PCR (qPCR), ultra-sensitive PCR, and/or the intact proviral DNA assay (IPDA) at baseline and time points throughout the study.
Changes in the number of copies per 10^6 T cells will be reported.
|
Baseline and 36 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Steven Deeks, MD, University of California, San Francisco
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- RNA Virus Infections
- Virus Diseases
- Blood-Borne Infections
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- Disease Attributes
- Slow Virus Diseases
- Urogenital Diseases
- Genital Diseases
- HIV Infections
- Infections
- Communicable Diseases
- Acquired Immunodeficiency Syndrome
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Cyclophosphamide
Other Study ID Numbers
- 20-31976
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed
Clinical Trials on LVgp120duoCAR-T cells, low dose
-
First Affiliated Hospital Xi'an Jiaotong UniversityEureka Therapeutics Inc.Unknown
-
First Affiliated Hospital Xi'an Jiaotong UniversityEureka Therapeutics Inc.UnknownCD19+ Lymphoma, B-Cell | CD19+ Leukemia, B-CellChina
-
AlloVirBaylor College of Medicine; The Methodist Hospital Research Institute; Center...Completed
-
AdaptimmuneActive, not recruitingMelanoma | Head and Neck Cancer | Gastric Cancer | Esophageal Cancer | Ovarian Cancer | Non-Small Cell Lung Cancer | Urinary Bladder Cancer | Synovial Sarcoma | Gastroesophageal Junction | Myxoid Round Cell LiposarcomaUnited States, Canada
-
Baylor College of MedicineThe Methodist Hospital Research Institute; Center for Cell and Gene Therapy...Active, not recruitingNon-Hodgkin's Lymphoma | B-Cell ALL | B-Cell CLLUnited States
-
Miltenyi Biomedicine GmbHICON plcActive, not recruitingB-cell Non Hodgkin LymphomaGermany
-
Sclnow Biotechnology Co., Ltd.RecruitingOsteoarthritis, KneeChina
-
Third Affiliated Hospital, Sun Yat-Sen UniversityUnknownHepatocellular CarcinomaChina
-
Maternal and Child Health Hospital of FoshanCompleted
-
Instituto de Investigación Sanitaria de la Fundación...Clinica Universidad de Navarra, Universidad de Navarra; Hospital Universitario... and other collaboratorsActive, not recruitingDiabetic Foot | Limb IschemiaSpain